Ángel Montero1, Raquel Ciérvide1, Philip Poortmans2,3. 1. Department of Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain. 2. Department of Radiation Oncology, Institut Curie, 25, rue d'Ulm, 75248, Paris Cedex 05, France. philip.poortmans@curie.fr. 3. Paris Sciences et Lettres - PSL University, Paris, France. philip.poortmans@curie.fr.
Abstract
PURPOSE OF REVIEW: Postmastectomy radiation therapy (PMRT) has been shown to reduce the risk of locoregional recurrences (LRR) and of distant metastases (DM) and to improve breast cancer-specific survival (BCSS) as well as overall survival (OS) in patients with locally advanced breast cancer who are considered high risk because of large tumors (> 5 cm) and/or presence of axillary lymph node involvement. RECENT FINDINGS: Controversy is still ongoing with respect to the indication of PMRT in the case of earlier stage invasive tumors in the presence of risk factors including young age, premenopausal status, presence of lymphovascular invasion (LVI), high tumor grade, or tumor size 2-5 cm. Simultaneously, the evolution of our understanding of breast cancer biology has led us to better identify patients for whom the administration of systemic treatment prior to surgery reduces tumor load, not only in the case of locally advanced tumors but also for earlier stages, namely in the case of unfavorable molecular subtypes. The role of PMRT in the context of these patients treated with primary systemic therapy (PST), especially after a good tumor response, is under evaluation by various studies. This review identifies factors that may permit PMRT omission in a selected group of patients after PST.
PURPOSE OF REVIEW: Postmastectomy radiation therapy (PMRT) has been shown to reduce the risk of locoregional recurrences (LRR) and of distant metastases (DM) and to improve breast cancer-specific survival (BCSS) as well as overall survival (OS) in patients with locally advanced breast cancer who are considered high risk because of large tumors (> 5 cm) and/or presence of axillary lymph node involvement. RECENT FINDINGS: Controversy is still ongoing with respect to the indication of PMRT in the case of earlier stage invasive tumors in the presence of risk factors including young age, premenopausal status, presence of lymphovascular invasion (LVI), high tumor grade, or tumor size 2-5 cm. Simultaneously, the evolution of our understanding of breast cancer biology has led us to better identify patients for whom the administration of systemic treatment prior to surgery reduces tumor load, not only in the case of locally advanced tumors but also for earlier stages, namely in the case of unfavorable molecular subtypes. The role of PMRT in the context of these patients treated with primary systemic therapy (PST), especially after a good tumor response, is under evaluation by various studies. This review identifies factors that may permit PMRT omission in a selected group of patients after PST.
Authors: Kristine R Broglio; Melanie Quintana; Margaret Foster; Melissa Olinger; Anna McGlothlin; Scott M Berry; Jean-François Boileau; Christine Brezden-Masley; Stephen Chia; Susan Dent; Karen Gelmon; Alexander Paterson; Daniel Rayson; Donald A Berry Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Abigail S Caudle; Wei T Yang; Savitri Krishnamurthy; Elizabeth A Mittendorf; Dalliah M Black; Michael Z Gilcrease; Isabelle Bedrosian; Brian P Hobbs; Sarah M DeSnyder; Rosa F Hwang; Beatriz E Adrada; Simona F Shaitelman; Mariana Chavez-MacGregor; Benjamin D Smith; Rosalind P Candelaria; Gildy V Babiera; Basak E Dogan; Lumarie Santiago; Kelly K Hunt; Henry M Kuerer Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Sean E McGuire; Ana M Gonzalez-Angulo; Eugene H Huang; Susan L Tucker; Shu-Wan C Kau; Tse-Kuan Yu; Eric A Strom; Julia L Oh; Wendy A Woodward; Welela Tereffe; Kelly K Hunt; Henry M Kuerer; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038